PharmaLogic Appoints Etienne Montagut as CEO Effective June 2025

• PharmaLogic has appointed Etienne Montagut as its new Chief Executive Officer, effective 1 June 2025.

• Steve Chilinski retires as CEO after 13 years and becomes Executive Chairman of the Board.

PharmaLogic Holdings Corp., a CDMO specialising in radiopharmaceuticals, has announced a leadership transition. Etienne Montagut, currently serving as President, will take over as President and Chief Executive Officer effective 1 June 2025.

The change follows the retirement of Steve Chilinski, who led the company for 13 years. He has assumed the role of Executive Chairman of the Board. Montagut brings more than 25 years of senior leadership experience in the pharmaceutical industry. His previous roles include executive positions at Lantheus, GE HealthCare, and Ipsen.

The appointment comes one year after Montagut joined PharmaLogic. The company stated that his track record in strategic transformation and growth across global markets positions him to lead its next phase.

Commenting on his appointment, Montagut said: “The company has experienced great success, and I’m very excited about our next chapter. PharmaLogic has talent, culture, technology, and resources to lead the future of radiopharmaceuticals and improve global patient access to novel diagnostics and therapies.”